AbbVie Inc (ABBV)vsCastle Biosciences Inc (CSTL)
ABBV
AbbVie Inc
$246.04
+0.89%
HEALTHCARE · Cap: $430.82B
CSTL
Castle Biosciences Inc
$32.03
+5.12%
HEALTHCARE · Cap: $928.40M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 17921% more annual revenue ($64.39B vs $357.28M). ABBV leads profitability with a 9.8% profit margin vs -5.4%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CSTL
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.04
$95.14 premium
Margin of Safety
+59.2%
Fair Value
$79.18
Current Price
$32.03
$47.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 20.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Earnings declined 51.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : CSTL
The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 20.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while CSTL is a growth play — different risk/reward profiles.
CSTL carries more volatility with a beta of 0.97 — expect wider price swings.
CSTL is growing revenue faster at 20.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 37/100) and 10.2% revenue growth. CSTL offers better value entry with a 59.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?